SCHEMBL7042006

SCHEMBL7042006

COC(=O)c1cc(NSC(=O)N2CCN(c3ccccc3Cl)CC2)c(OC)nc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.40
GAA P10253 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
BLM P54132 1/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40
MAPK1 P28482 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7042753 0.91 MAPT (0.47) SMN1; SMN2GAAPOLBPKMKMT2A
SCHEMBL7044666 0.89 SMN1; SMN2 (0.39) SMN1; SMN2GAAL3MBTL1HTR1AKMT2A
SCHEMBL7041121 0.88 MAPT (0.48) RBP4SMN1; SMN2GAAL3MBTL1MAPK1
SCHEMBL6653957 0.84 KDM4E (0.52) RBP4SMN1; SMN2GAAL3MBTL1POLB
SCHEMBL7040077 0.84 MAPT (0.41) SMN1; SMN2GAAL3MBTL1MAPK1KMT2A
SCHEMBL7038717 0.84 KMT2A (0.41) SMN1; SMN2GAAL3MBTL1PKMMAPK1
SCHEMBL7044475 0.83 GAA (0.41) SMN1; SMN2GAAL3MBTL1MAPK1KMT2A
SCHEMBL7041068 0.81 KMT2A (0.39) SMN1; SMN2GAAL3MBTL1KMT2AMAPT
SCHEMBL7046056 0.81 GAA (0.39) SMN1; SMN2GAAL3MBTL1MAPK1KMT2A
SCHEMBL7041089 0.79 THRB (0.38) L3MBTL1HTR1AHTR2AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS RBP4 4204/4885SMN1; SMN2 2466/4885GAA 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.